Lanraplenib (GS-9876) is a highly selective oral inhibitor (=9.5 nM) for the study of inflammatory diseases.Lanraplenib (GS-9876) inhibits activity in platelets via glycoprotein VI (GPVI) receptors without prolonging bleeding time (BT) in monkeys or humans.